S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
Advanced Micro Devices (NASDAQ: AMD) Stock Hasn’t Priced In Bitcoin (BTC) Fueled GPU Demand
Fusion Fuel Green Limited (NASDAQ: HTOO) Stock is a Newly Minted Green Hydrogen Play
NetEase (NASDAQ:NTES): A Chinese Growth Stock to Add Now
General Motors (NYSE: GM) Completes 200% Gain And Still Has Room To Run
JB Hunt (NASDAQ:JBHT) Crashes After Mixed Quarter
United (NYSE:UAL) Stock Is Telling Two Stories, Be Sure You Choose the Right One
Will Boston Beer (NYSE: SAM) Shares Make Another Run in 2021?
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
Advanced Micro Devices (NASDAQ: AMD) Stock Hasn’t Priced In Bitcoin (BTC) Fueled GPU Demand
Fusion Fuel Green Limited (NASDAQ: HTOO) Stock is a Newly Minted Green Hydrogen Play
NetEase (NASDAQ:NTES): A Chinese Growth Stock to Add Now
General Motors (NYSE: GM) Completes 200% Gain And Still Has Room To Run
JB Hunt (NASDAQ:JBHT) Crashes After Mixed Quarter
United (NYSE:UAL) Stock Is Telling Two Stories, Be Sure You Choose the Right One
Will Boston Beer (NYSE: SAM) Shares Make Another Run in 2021?
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
Advanced Micro Devices (NASDAQ: AMD) Stock Hasn’t Priced In Bitcoin (BTC) Fueled GPU Demand
Fusion Fuel Green Limited (NASDAQ: HTOO) Stock is a Newly Minted Green Hydrogen Play
NetEase (NASDAQ:NTES): A Chinese Growth Stock to Add Now
General Motors (NYSE: GM) Completes 200% Gain And Still Has Room To Run
JB Hunt (NASDAQ:JBHT) Crashes After Mixed Quarter
United (NYSE:UAL) Stock Is Telling Two Stories, Be Sure You Choose the Right One
Will Boston Beer (NYSE: SAM) Shares Make Another Run in 2021?
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
Advanced Micro Devices (NASDAQ: AMD) Stock Hasn’t Priced In Bitcoin (BTC) Fueled GPU Demand
Fusion Fuel Green Limited (NASDAQ: HTOO) Stock is a Newly Minted Green Hydrogen Play
NetEase (NASDAQ:NTES): A Chinese Growth Stock to Add Now
General Motors (NYSE: GM) Completes 200% Gain And Still Has Room To Run
JB Hunt (NASDAQ:JBHT) Crashes After Mixed Quarter
United (NYSE:UAL) Stock Is Telling Two Stories, Be Sure You Choose the Right One
Will Boston Beer (NYSE: SAM) Shares Make Another Run in 2021?
Log in
OTCMKTS:STDAF

STADA Arzneimittel Aktiengesellschaft Stock Forecast, Price & News

$110.42
0.00 (0.00 %)
(As of 01/19/2021 12:00 AM ET)
Add
Compare
Today's Range
$110.42
Now: $110.42▼
$110.42
50-Day Range
$110.42
MA: $110.42▼
$110.42
52-Week Range
$75.15
Now: $110.42▼
$115.00
VolumeN/A
Average VolumeN/A
Market Capitalization$6.88 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.54
STADA Arzneimittel AG engages in the provision of healthcare and pharmaceutical products. It operates through the Generics and Branded Products segments. The Generics segment produces and distributes generic drugs. The Branded Products segment sells branded healthcare products and medicines. Its brands include Zoflora, Grippostad, Nizoral, and Covonia. The company was founded on March 14, 1895 and is headquartered in Bad Vilbel, Germany.
STADA Arzneimittel Aktiengesellschaft logo

MarketRank™

Overall MarketRank™

0.40 out of 5 stars

Medical Sector

1681st out of 1,928 stocks

Medicinals & Botanicals Industry

26th out of 33 stocks

Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:STDAF
Previous SymbolNASDAQ:STDAF
CUSIPN/A
CIKN/A
Webwww.stada.com
Phone(496) 101-6030
Employees11,100

Debt

Debt-to-Equity Ratio2.26
Current Ratio1.49
Quick Ratio0.93

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.92 billion
Price / SalesN/A
Cash Flow$11.26 per share
Price / Cash Flow9.81
Book Value$21.48 per share
Price / Book5.14

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding SharesN/A
Market Cap$6.88 billion
Next Earnings Date3/10/2021 (Estimated)
OptionableNot Optionable
$110.42
0.00 (0.00 %)
(As of 01/19/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive STDAF News and Ratings via Email

Sign-up to receive the latest news and ratings for STDAF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











STADA Arzneimittel Aktiengesellschaft (OTCMKTS:STDAF) Frequently Asked Questions

How has STADA Arzneimittel Aktiengesellschaft's stock price been impacted by COVID-19?

STADA Arzneimittel Aktiengesellschaft's stock was trading at $88.92 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, STDAF stock has increased by 24.2% and is now trading at $110.42.
View which stocks have been most impacted by COVID-19.

What stocks does MarketBeat like better than STADA Arzneimittel Aktiengesellschaft?

Wall Street analysts have given STADA Arzneimittel Aktiengesellschaft a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but STADA Arzneimittel Aktiengesellschaft wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is STADA Arzneimittel Aktiengesellschaft's next earnings date?

STADA Arzneimittel Aktiengesellschaft is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021.
View our earnings forecast for STADA Arzneimittel Aktiengesellschaft.

Who are some of STADA Arzneimittel Aktiengesellschaft's key competitors?

Some companies that are related to STADA Arzneimittel Aktiengesellschaft include Canopy Growth (CGC), Aphria (APHA), Cronos Group (CRON), Tilray (TLRY), USANA Health Sciences (USNA), Aurora Cannabis (ACB), HEXO (HEXO), Sundial Growers (SNDL), Canopy Rivers (RIV), ChromaDex (CDXC), Charlie's (CHUC), MediWound (MDWD), Natural Alternatives International (NAII), Glucose Health (GLUC) and True Drinks (TRUU).
View all of STDAF's competitors.

Who are STADA Arzneimittel Aktiengesellschaft's key executives?

STADA Arzneimittel Aktiengesellschaft's management team includes the following people:
  • Peter Goldschmidt, Chairman-Executive Board
  • Wolfgang Ollig, Chief Financial Officer
  • Miguel Pagan Fernandez, Chief Technical Officer
  • Robert Knerr, EVP-Global Portfolio & Product Development
  • Simone Berger, Executive Vice President-Human Resources

What is STADA Arzneimittel Aktiengesellschaft's stock symbol?

STADA Arzneimittel Aktiengesellschaft trades on the OTCMKTS under the ticker symbol "STDAF."

How do I buy shares of STADA Arzneimittel Aktiengesellschaft?

Shares of STDAF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is STADA Arzneimittel Aktiengesellschaft's stock price today?

One share of STDAF stock can currently be purchased for approximately $110.42.

How big of a company is STADA Arzneimittel Aktiengesellschaft?

STADA Arzneimittel Aktiengesellschaft has a market capitalization of $6.88 billion and generates $2.92 billion in revenue each year. STADA Arzneimittel Aktiengesellschaft employs 11,100 workers across the globe.

What is STADA Arzneimittel Aktiengesellschaft's official website?

The official website for STADA Arzneimittel Aktiengesellschaft is www.stada.com.

How can I contact STADA Arzneimittel Aktiengesellschaft?

STADA Arzneimittel Aktiengesellschaft's mailing address is Stadastrasse 2-18, Bad Vilbel 2M, 61118. The company can be reached via phone at (496) 101-6030 or via email at [email protected]

This page was last updated on 1/20/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.